Andrew Gengos was named Chief Financial Officer of Immuneering Corp. As of November 10, 2026, Immuneering Corp has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 15, 2026 to November 9, 2026, naming 3 appointments (Form 8-K, June 15, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Immuneering Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Immuneering Corp reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-15 to 2026-11-09. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Immuneering Corp files it.
Also on the record for Immuneering Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 28, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 6.7% of the class | 5%+ stakes | Source |
| January 22, 2026 | Stake report, Schedule 13G/A, by BENJAMIN J. ZESKIND | 6.6% of the class | 5%+ stakes | Source |
| January 15, 2026 | Stake report, Schedule 13G/A, by Empery Asset Management, LP | 4.99% of the class | 5%+ stakes | Source |
| October 21, 2025 | Stake report, Schedule 13G, by Empery Asset Management, LP | 8.83% of the class | 5%+ stakes | Source |
| October 7, 2025 | Stake report, Schedule 13G, by FMR LLC | 14.5% of the class | 5%+ stakes | Source |
| October 3, 2025 | Stake report, Schedule 13G, by HBM Healthcare Investments (Cayman) Ltd. | 5.7% of the class | 5%+ stakes | Source |
| September 9, 2025 | Form D, private offering | $25M sold | Form D page | Source |
Selling to them or working with them? See who runs Immuneering Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on Immuneering Corp and the records around it.
Immuneering Corp elsewhere on the record
- Form D filing Sep 2025
- Who owns it
Companies that share a holder
- HBM Healthcare Investments (Cayman) Ltd. also filed stake reports on 7 other companies: Chemomab Therapeutics Ltd. (Sep 2026), ALX ONCOLOGY HOLDINGS INC (May 2026), IO Biotech, Inc. (Apr 2026)
- Empery Asset Management, LP also filed stake reports on 21 other companies: Dyadic International Inc. (Oct 2026), Femasys Inc. (Oct 2026), Clene Inc. (Oct 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Immuneering Corp
Get an email when Immuneering Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Immuneering Corp?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Immuneering Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Immuneering Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-09 | In | 8-K, 2026-11-09 | |||
| 2026-06-15 | In | Chief Financial Officer | 8-K, 2026-06-15 | ||
| 2026-06-15 | In | 8-K, 2026-06-15 |
Who leads Immuneering Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Andrew Gengos, appointed (filed 2026-06-15).
New leaders reset buying decisions — get the Full Report on Immuneering Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Immuneering Corp, with the record behind each one.
Find candidates like Chief Financial Officer at Immuneering CorpEvery change, in the filing's words
Appointed: Grant C. Bogle
On November 9, 2026, the Board of Directors (the "Board") of Immuneering Corporation (the "Company") appointed Grant C. Bogle, MBA, to serve as a member of the Company's Board as a Class III Director.
- Mr. Bogle will receive compensation in accordance with the Company's compensation arrangements for non-employee directors.
- Mr. Bogle has not been appointed to a committee of the Board of Directors at this time.
- Mr. Bogle has also entered into the Company's standard indemnification agreement for directors and officers.
Appointed: Andrew Gengos, Chief Financial Officer
On June 11, 2026, the Board of Directors (the "Board") of Immuneering Corporation (the "Company") appointed Andrew Gengos as th e Chief Financial Officer and Treasurer of t he Company, to become effective on the commencement of his employment with the Company, which is expected to be on or before July 16, 2026 (the date Mr. Gengos actually commences employment with the Company, the "Effective Date").
Appointed: Andrew Gengos
The Board also designated Mr. Gengos as the Company's principal financial officer as of the Effective Date, succeeding Mallory Morales in such role.
- In her ongoing role as Senior Vice President Finance, Chief Accounting Officer, Ms. Morales will continue to serve as the Company's principal accounting officer.
- Mr. Gengos, age 61, joins the Company from Terns Pharmaceuticals, where he served as Chief Financial Officer from February 2025 to May 2026.
- Mr. Gengos previously served as the Chief Financial Officer and Chief Business Officer of LeonaBio Inc., a publicly-traded biopharmaceutical company, from May 2023 to October 2024.
- From February 2020 to February 2023, Mr. Gengos served as the Chief Business Officer at Cyteir Therapeutics, Inc., a formerly publicly-traded biopharmaceutical company, where he led the finance team that took the company public.
- In addition, Mr. Gengos held Chief Executive Officer roles at ImmunoCellular Therapeutics, Ltd. and Neuraltus Pharmaceuticals, Inc., where he provided strategic and financial leadership across multiple therapeutic areas, including oncology and neurodegenerative disease.
- Earlier, Mr. Gengos was Vice President of Strategy and Corporate Development at Amgen Inc. for eight years.
- Mr. Gengos started his career at Morgan Stanley before moving on to McKinsey & Co., where he advanced from associate to senior engagement manager.
- Mr. Gengos holds an M.B.A. from the UCLA Anderson School of Management and a B.S. in Chemical Engineering from the Massachusetts Institute of Technology.
Tools for this story
Each opens in a new tab, filled in for Immuneering Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.